Study shows medication benefits in cat allergy sufferers
September 1st 2005Boston—Epinastine HCl 0.05% ophthalmic solution (Elestat, Inspire/Allergan) safely and effectively relieves the signs and symptoms of allergic conjunctivitis due to cat dander, according to the results of a clinical trial conducted by researchers from New England Eye Center, Tufts University, Boston.
Low-dose corticosteroid targets acute allergic conjunctivitis
September 1st 2005Orangeburg, NY—The low-dose modified corticosteroid loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb) is effectively used during the acute phase of seasonal allergic conjunctivitis, according to Ayman Matta, MD, PC, FACS.
Mast cell stabilizer ideal for giant papillary conjunctivitis
September 1st 2005Miami—Despite the presence of new therapies for ocular allergies on the market, nedocromil sodium ophthalmic solution 2% (Alocril, Allergan) may be an effective choice for some patients, said William Trattler, MD, in private practice at the Center for Excellence in Eye Care, Miami.
Artificial tears can enhance vision in patients with dry eye
September 1st 2005Fort Lauderdale, FL-Contrast sensitivity and visual acuity improved in a small group of subjects with dry eye following instillation of one of three types of artificial tears administered in a study of tear layer disruption. The fact that only one solution produced an enhancement in visual performance suggests that practitioners need to match a patient's dry eye subtype with an appropriate artificial tear supplement to gain the most improvement, said William H. Ridder III, OD, PhD, FAAO.
Cyclosporine brings rapid relief for mild-to-moderate dry eye
September 1st 2005Washington, DC-Initiation of topical cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) is associated with rapid onset of relief in most LASIK patients with mild-to-moderate chronic dry eye, said Karl G. Stonecipher, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Dry eye a constantly changing landscape
September 1st 2005Washington, DC-Dry eye disease affects millions of people worldwide and with that has come a recent greater awareness among patients that it is indeed a problem. As the recognition of the magnitude of dry eye is changing, so too has knowledge of its pathogenesis, the technology facilitating diagnosis, and the drugs that are becoming available to treat it. General ophthalmologists will be increasingly challenged to learn more about the disease and the best ways to treat individual patients, according to Michael Lemp, MD.
Genetic testing may be key to helping rare eye diseases
September 1st 2005Orlando—When a child receives the diagnosis of Leber's congenital amaurosis (LCA) or another genetically based disease, too often parents hear from the ophthalmologist that nothing can be done. Whether the doctor intends to deliver such a negative message or conveys it inadvertently by using cold, clinical terminology, it is the wrong message, according to Edwin M. Stone, MD, PhD.
High-frequency UBM helpful tool in strabismus reoperation
September 1st 2005Orlando—The high-frequency ultrasound biomicroscope (UBM) can reliably estimate the distance of horizontal muscle insertion from the limbus in eyes that had previous strabismus surgery on the same muscle, according to Shuan H. Dai, MB, BS, FRANZCO, a pediatric ophthalmologist.
Pegaptanib earns praise as 'product of the year'
September 1st 2005New York—Pegaptanib sodium injection (Macugen) has won recognition as a major scientific breakthrough from an organization accustomed to novel pharmaceutical products. The drug, the first FDA-approved treatment for wet age-related macular degeneration (AMD), was named Innovative Pharmaceutical Product of the Year at the 2005 Pharmaceutical Achievement Awards.
Are we no longer a nation built upon risk?
September 1st 2005At a recent meeting of department directors, the president of my university, William Brody, MD, PhD, made an offhand comment that resonated with me. He noted that "the citizens of the United States, a nation built upon risk, seem no longer willing to accept any risk."
Surgical intervention beneficial to adult strabismus
September 1st 2005Orlando—A questionnaire administered to adults who underwent surgery for strabismus showed that most patients believed any disabilities related to this condition improved after the procedure, said George R. Beauchamp, MD, FACS, professor of clinical ophthalmology, University of Texas Southwestern Medical School, Dallas.
Visual complaints seen with neurodegenerative diseases
August 15th 2005St. Louis—Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy, are characterized by visual complaints, which must be assessed carefully to establish the correct diagnosis.
Intravitreal Sod2 injections able to rescue RGCs in mice
August 15th 2005Fort Lauderdale, FL—A potential new strategy has been proposed to treat optic neuritis and multiple sclerosis, namely, delivery of the superoxide dismutase (Sod) 2 gene. Intravitreal Sod2 injections in mice suppressed myelin fiber injury and rescued the retinal ganglion cells (RGCs) for up to 1 year after the inoculation, according to John Guy, MD.
Knowing services aspect key to marketing direction
August 15th 2005Understanding the fundamentals of services marketing is extremely useful for the optimal marketing of a medical practice. Basic knowledge in this area is also helpful when studying the marketing approach of your competitors. Additionally, you may consider these concepts when analyzing ads for which you are the targeted customer.